Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway

Abstract

Human Aurora2 was originally identified by its close homology to yeast IPL1 and fly aurora, which are key regulators of chromosome segregation and a family of serine/threonine kinases. Here we demonstrate that the Aurora2 protein is degraded rapidly after G2/M phase release in mammalian cells. Aurora2 protein has a rapid turnover rate with a half-life of approximately 2 h. In eukaryotic cells, the ubiquitin-proteasome pathway is the major mechanism for the targeted degradation of unstable proteins. The treatment of mammalian cells with proteasome inhibitors blocks Aurora2 degradation. Furthermore, Aurora2 is polyubiquitinated in vivo and in vitro using anaphase-promoting complex (APC). These results demonstrate that Aurora2 protein is turned over through the APC-ubiquitin-proteasome pathway.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Amon A, Irniger S and Nasmyth K . 1994 Cell 77: 1037–1050

  • Biggins S, Severin FF, Bhalla N, Sassoon I, Hyman AA and Murray AW . 1999 Genes Dev 13: 532–544

  • Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ and Plowman GD . 1998 EMBO J 17: 3052–3065

  • Bischoff JR and Plowman GD . 1999 Trends Cell Biol 9: 454–459

  • Campanero MR and Flemington EK . 1997 Proc Natl Acad Sci USA 94: 2221–2226

  • Ciechanover A . 1994 Cell 79: 13–21

  • Ciechanover A . 1998 EMBO J 17: 7151–7160

  • Fang G, Yu H and Kirschner MW . 1998 Mol Cell 2: 163–171

  • Fenteany G and Schreiber SL . 1998 J Biol Chem 273: 8545–8548

  • Francisco L, Wang W and Chan CS . 1994 Mol Cell Biol 14: 4731–4740

  • Glotzer M, Murray AW and Kirschner MW . 1991 Nature 349: 132–138

  • Glover DM, Leibowitz MH, McLean DA and Parry H . 1995 Cell 81: 95–105

  • Gopalan G, Chan CS and Donovan PJ . 1997 J Cell Biol 138: 643–656

  • Honda R and Yasuda H . 1999 EMBO J 18: 22–27

  • Kimura M, Kotani S, Hattori T, Sumi N, Yoshioka T, Todokoro K and Okano Y . 1997 J Biol Chem 272: 13766–13771

  • Koepp DM, Harper JW and Elledge SJ . 1999 Cell 97: 431–434

  • Maki CG, Huibregtse JM and Howley PM . 1996 Cancer Res 56: 2649–2654

  • Murray AW, Solomon MJ and Kirschner MW . 1989 Nature 339: 280–286

  • Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M . 1995 Science 269: 682–685

  • Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D and Goldberg AL . 1994 Cell 78: 761–771

  • Salghetti SE, Kim SY and Tansey WP . 1999 EMBO J 18: 717–726

  • Shindo M, Nakano H, Kuroyanagi H, Shirasawa T, Mihara M, Gilbert DJ, Jenkins NA, Copeland NG, Yagita H and Okumura K . 1998 Biochem Biophys Res Commun 244: 285–292

  • Stewart E, Kobayashi H, Harrison D and Hunt T . 1994 EMBO J 13: 584–594

  • Townsley FM, Aristarkhov A, Beck S, Hershko A and Ruderman JV . 1997 Proc Natl Acad Sci USA 94: 2362–2367

  • Treier M, Staszewski LM and Bohmann D . 1994 Cell 78: 787–798

  • Urano T, Emkey R and Feig LA . 1996 EMBO J 15: 810–816

  • Urano T, Furukawa K and Shiku H . 1993 Oncogene 8: 1371–1376

  • Varshavsky A . 1997 Trends Biochem Sci 22: 383–387

  • Yanai A, Arama E, Kilfin G and Motro B . 1997 Oncogene 14: 2493–2950

  • Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR and Sen S . 1998 Nat Genet 20: 189–193

Download references

Acknowledgements

We thank Drs Dirk Bohmann (European Molecular Biology Laboratory, Heidelberg, Germany) for the histidine-tagged ubiquitin expression vector (pMT107) and Larry A Feig (Tufts University, Boston, MA, USA) for anti-glu monoclonal and anti-Ras polyclonal antibodies. This work was supported by grant-in-aids for Scientific Research and Core of Excellence from the Ministry of Education, Science, Sports and Culture of Japan, and Aichi Cancer research foundation.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Honda, K., Mihara, H., Kato, Y. et al. Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway. Oncogene 19, 2812–2819 (2000). https://doi.org/10.1038/sj.onc.1203609

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203609

Keywords

This article is cited by

Search

Quick links